

Recent Advances in Sarcopenia Therapies: A Comprehensive Review on Pathogenesis and Treatment Innovations

Timtima Doudeselva*

Department of Surgery, University of Bucharest, 050657 Bucharest, Romania

Abstract

Sarcopenia, characterized by progressive loss of muscle mass, strength and function with aging, poses significant challenges to the health and independence of older adults. This comprehensive review provides an overview of recent advances in sarcopenia therapies, encompassing insights into pathogenesis mechanisms and emerging treatment innovations. Understanding the multifactorial etiology of sarcopenia, including age-related hormonal changes, chronic inflammation, mitochondrial dysfunction and physical inactivity, is essential for developing targeted therapeutic interventions. Recent research has elucidated the role of molecular pathways, such as the Insulin-like Growth Factor-1 (IGF-1) axis, myostatin signaling and protein synthesis pathways, in the pathogenesis of sarcopenia, offering potential targets for pharmacological and lifestyle interventions. Treatment innovations include resistance training, protein supplementation, pharmacological agents targeting myostatin inhibition and hormonal therapies aiming to restore anabolic hormone levels. Additionally, emerging modalities such as nutraceuticals, dietary interventions and regenerative medicine approaches hold promise for preserving muscle mass and function in aging populations. This review synthesizes current evidence on sarcopenia pathogenesis and treatment strategies, highlighting opportunities for personalized and multidimensional approaches to sarcopenia management in clinical practice.

Keywords: Sarcopenia • Muscle aging • Muscle dysfunction • Pharmacotherapy

Introduction

Sarcopenia, characterized by the progressive loss of muscle mass, strength and function with advancing age, has emerged as a significant public health concern, particularly in aging populations worldwide. This age-related condition not only diminishes quality of life but also increases the risk of falls, fractures, disability and mortality among older adults. As the global population ages, the prevalence of sarcopenia is expected to rise, highlighting the urgent need for effective prevention and management strategies. This comprehensive review aims to provide an overview of recent advances in sarcopenia therapies, encompassing insights into pathogenesis mechanisms and emerging treatment innovations. Understanding the complex etiology of sarcopenia is essential for developing targeted therapeutic interventions. While aging is the primary risk factor for sarcopenia, its pathogenesis is multifactorial, involving a combination of hormonal changes, chronic inflammation, oxidative stress, mitochondrial dysfunction and physical inactivity. Recent research has shed light on the molecular mechanisms underlying muscle loss in sarcopenia, including dysregulation of the Insulin-like Growth Factor-1 (IGF-1) axis, activation of myostatin signaling and impaired protein synthesis pathways. These insights offer potential targets for pharmacological interventions aimed at preserving muscle mass and function in older adults. In addition to pharmacological approaches, lifestyle interventions such as resistance training and protein supplementation have demonstrated efficacy in attenuating age-related muscle loss and improving physical function in sarcopenic individuals. Furthermore, emerging modalities such as nutraceuticals, dietary interventions

and regenerative medicine approaches hold promise for enhancing muscle health and resilience in aging populations. This review will synthesize current evidence on sarcopenia pathogenesis and treatment strategies, providing clinicians and researchers with valuable insights into the latest developments in sarcopenia management [1,2].

Literature Review

Recent research has expanded our understanding of the pathogenesis of sarcopenia, revealing intricate molecular mechanisms underlying age-related muscle loss. Dysregulation of the IGF-1 signaling pathway, characterized by decreased circulating levels of IGF-1 and impaired muscle sensitivity to IGF-1, contributes to the decline in muscle protein synthesis and regeneration observed in sarcopenia. Moreover, upregulation of myostatin, a negative regulator of muscle growth, inhibits muscle satellite cell activation and promotes muscle wasting in aging individuals. Pharmacological interventions targeting these molecular pathways have shown promise in preclinical and clinical studies. For example, Selective Androgen Receptor Modulators (SARMs) and myostatin inhibitors have demonstrated efficacy in increasing muscle mass and strength in sarcopenic patients. Hormonal therapies such as testosterone replacement have also been investigated for their potential to improve muscle function and physical performance in older adults [3].

In addition to pharmacotherapy, lifestyle interventions remain cornerstone strategies for sarcopenia management. Resistance training, characterized by progressive overload of muscle fibers, stimulates muscle protein synthesis and hypertrophy, leading to gains in muscle mass and strength. Protein supplementation, particularly in conjunction with resistance training, enhances muscle protein synthesis and promotes muscle accretion in older adults. Furthermore, emerging modalities such as nutraceuticals, dietary interventions and regenerative medicine approaches offer novel avenues for sarcopenia prevention and treatment. Nutritional supplements containing amino acids, creatine and omega-3 fatty acids have been shown to attenuate muscle loss and improve physical function in aging populations. Dietary interventions such as caloric restriction and intermittent fasting may also exert beneficial effects on muscle health through mechanisms such as autophagy induction and mitochondrial biogenesis. Regenerative medicine strategies, including stem cell therapy and tissue engineering, hold promise for restoring muscle mass

*Address for Correspondence: Timtima Doudeselva, Department of Surgery, University of Bucharest, 050657 Bucharest, Romania, E-mail: timtimadoudeselva@hotmail.com

Copyright: © 2024 Doudeselva T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 02 March, 2024, Manuscript No. jppr-24-132690; **Editor Assigned:** 04 March, 2024, PreQC No. P-132690; **Reviewed:** 16 March, 2024, QC No. Q-132690; **Revised:** 21 March, 2024, Manuscript No. R-132690; **Published:** 28 March, 2024, DOI: 10.37421/2573-0312.2024.9.384

and function in sarcopenic individuals by promoting muscle regeneration and repair [4].

Discussion

The discussion section of this review serves to contextualize the findings presented in the introduction and literature review, highlighting the significance of recent advances in sarcopenia therapies and addressing key considerations for clinical practice and future research. Recent developments in sarcopenia therapies represent a critical step forward in addressing the growing burden of age-related muscle loss and its associated consequences. By elucidating the molecular mechanisms underlying sarcopenia pathogenesis, researchers have identified novel targets for pharmacological interventions aimed at preserving muscle mass and function in aging populations. Additionally, lifestyle interventions such as resistance training and protein supplementation remain foundational strategies for sarcopenia management, offering safe, cost-effective approaches to attenuating muscle loss and improving physical performance in older adults [5].

However, several challenges and considerations must be addressed to optimize the effectiveness and accessibility of sarcopenia therapies. One key consideration is the need for personalized and multidimensional approaches to sarcopenia management, recognizing the heterogeneity of the aging process and individual responses to interventions. Clinicians must consider factors such as comorbidities, functional status, nutritional status and psychosocial factors when designing treatment plans for sarcopenic patients, tailoring interventions to address specific needs and goals. Furthermore, the implementation of sarcopenia therapies in clinical practice requires interdisciplinary collaboration and coordinated care delivery. Healthcare providers across disciplines, including primary care physicians, geriatricians, rehabilitation specialists and nutritionists, must work together to assess and manage sarcopenia comprehensively, addressing both physical and psychosocial aspects of the condition. Additionally, patient education and empowerment are essential for promoting adherence to treatment regimens and fostering self-management skills among sarcopenic individuals [6].

Conclusion

In conclusion, this comprehensive review has provided an overview of recent advances in sarcopenia therapies, encompassing insights into pathogenesis mechanisms and treatment innovations. Sarcopenia, characterized by age-related loss of muscle mass, strength and function, poses significant challenges to the health and independence of older adults. Recent research has deepened our understanding of the molecular mechanisms underlying sarcopenia, offering potential targets for pharmacological interventions aimed at preserving muscle mass and function in aging populations. Moreover, lifestyle interventions such as resistance training and protein supplementation remain foundational strategies for sarcopenia management, offering safe,

accessible approaches to attenuating muscle loss and improving physical performance in older adults. Emerging modalities such as nutraceuticals, dietary interventions and regenerative medicine approaches hold promise for further enhancing muscle health and resilience in aging populations. Moving forward, interdisciplinary collaboration, personalized treatment approaches and patient-centered care will be essential for optimizing the effectiveness and accessibility of sarcopenia therapies. By addressing remaining challenges, refining therapeutic strategies and translating scientific discoveries into clinical practice, we can continue to advance the field of sarcopenia management and improve the health and wellbeing of older adults worldwide.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Terry, Erin E., Xiping Zhang, Christy Hoffmann and Laura D. Hughes, et al. "Transcriptional profiling reveals extraordinary diversity among skeletal muscle tissues." *Elife* 7 (2018): e34613.
2. Frontera, Walter R. and Julien Ochala. "Skeletal muscle: A brief review of structure and function." *Calcif Tissue Int* 96 (2015): 183-195.
3. Cai, Zijun, Di Liu, Yuntao Yang and Wenqing Xie, et al. "The role and therapeutic potential of stem cells in skeletal muscle in sarcopenia." *Stem Cell Res Ther* 13 (2022): 28.
4. Kalinkovich, Alexander, Maria Becker and Gregory Livshits. "New horizons in the treatment of age-associated obesity, sarcopenia and osteoporosis." *Drugs Aging* 39 (2022): 673-683.
5. Bellanti, Francesco, Aurelio Lo Buglio and Gianluigi Vendemiale. "Muscle delivery of mitochondria-targeted drugs for the treatment of sarcopenia: Rationale and perspectives." *Pharmaceutics* 14 (2022): 2588.
6. Sousa-Victor, Pedro and Pura Muñoz-Cánoves. "Regenerative decline of stem cells in sarcopenia." *Mol Asp Med* 50 (2016): 109-117.

How to cite this article: Doudeselva, Tintima. "Recent Advances in Sarcopenia Therapies: A Comprehensive Review on Pathogenesis and Treatment Innovations." *Physiother Rehabil* 9 (2024): 384.